TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update

Core Viewpoint - TG Therapeutics, Inc. will hold a conference call on February 26, 2026, to discuss its financial results for Q4 and full year 2025, along with a business outlook for 2026 [1]. Group 1: Conference Call Details - The conference call will take place at 8:30 AM ET and will be hosted by Michael S. Weiss, Chairman and CEO [1]. - Participants can join the call by dialing 1-877-407-8029 (U.S.) or 1-201-689-8029 (outside the U.S.) [2]. - A live webcast will be available on the company's website, and an audio recording will be accessible for 30 days post-call [2][3]. Group 2: Company Overview - TG Therapeutics is a biotechnology company focused on developing and commercializing treatments for B-cell diseases [4]. - The company has received FDA approval for BRIUMVI® (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis [4]. - BRIUMVI has also been approved by several regulatory agencies outside the U.S. for treating adult patients with active relapsing multiple sclerosis [4].